Smartest Doc
Short- and long-term outcomes in babies born after antenatal magnesium treatment
Journal of Obstetrics and Gynaecology Research, 07/15/2011
Mitani M et al. – Long–term tocolysis with magnesium sulfate is not a significant factor related to the occurrence of neonatal and infantile adverse outcomes. Further study is needed to clarify the dose–response effect of magnesium sulfate.
Methods- A case–control study was performed to examine the effect of long–term tocolysis with MgSO4.
- Long–term neonatal and infantile adverse outcomes were defined as one of the following: intraventricular hemorrhage, periventricular leukomalacia, cerebral palsy and infantile death.
- Data were analyzed for 425 cases (236 who received magnesium sulfate and 189 control cases who did not).
- Perinatal deaths included 13 cases that had received magnesium (5.5%) and 17 control cases (9.0%).
- Long–term neonatal and infantile adverse outcomes were noted in 80 cases.
- The factor associated with an increased risk of combined adverse outcome after adjustment for confounding effects was the administration of corticosteroids (adjusted odds ratio [OR] 0.47, 95% confidence interval [CI] 0.27–0.81), but not magnesium sulfate (OR 0.82, 95% CI 0.48–1.40).
- In the subgroup that also received ritodrine (n = 315), magnesium sulfate was given to 195 cases.
- In this group, the factor associated with an increased risk of combined adverse outcome (n = 64) after adjustment for the confounding effects was also corticosteroids (adjusted OR 0.25, 95% CI 0.13–0.49), but magnesium sulfate was not associated with an increase in risk (OR 0.64, 95% CI 0.34–1.22).
